List view / Grid view
AstraZeneca plc is an Anglo–Swedish multinational pharmaceutical and biopharmaceutical company.
In 2013, it moved its headquarters to Cambridge, United Kingdom, and concentrated its R&D in three sites: Cambridge, Gaithersburg, Maryland (location of MedImmune) for work on biopharmaceuticals, and Mölndal (near Gothenburg) in Sweden, for research on traditional chemical drugs. In 2015, it was the eighth-largest drug company in the world based on sales revenue.
AstraZeneca has a portfolio of products for major disease areas including cancer, cardiovascular, gastrointestinal, infection, neuroscience, respiratory and inflammation. The company was founded in 1999 through the merger of the Swedish Astra AB and the English Zeneca Group (itself formed by the demerger of the pharmaceutical operations of Imperial Chemical Industries in 1993). It has made numerous corporate acquisitions, including Cambridge Antibody Technology (in 2006), MedImmune (in 2007), Spirogen (in 2013) and Definiens (by MedImmune in 2014).
20 June 2016 | By Victoria White, Digital Content Producer
A Phase II expansion of the ongoing TATTON trial has been initiated to evaluate savolitinib (AZD6094) in epidermal growth factor receptor (EGFR) mutant non-small cell lung cancer (NSCLC) patients.
9 June 2016 | By Victoria White, Digital Content Producer
AGI is to acquire the rights, outside the US, to AstraZeneca’s portfolio of anaesthetics for an upfront consideration of $520 million...
2 June 2016 | By Victoria White, Digital Content Producer
Grünenthal has entered into a licensing agreement with AstraZeneca for the exclusive rights to Zurampic (lesinurad) in Europe and Latin America...
27 May 2016 | By Victoria White, Digital Content Producer
The Phase III FALCON trial compared Faslodex to Arimidex for the treatment of locally-advanced or metastatic breast cancer, in post-menopausal women...
12 May 2016 | By Victoria White, Digital Content Producer
The FDA has granted Orphan Drug Designation for selumetinib for adjuvant treatment of patients with stage III or IV differentiated thyroid cancer (DTC)...
In this Mass Spectrometry In-Depth Focus: Novel trends in glycosylation analysis of biotherapeutics by mass spectrometry; The use of mass spectrometry for the characterisation of proteins in small molecule drug discovery; Mass Spectrometry Q&A...
26 April 2016 | By Victoria White, Digital Content Producer
Under the terms of the agreement, Ironwood Pharmaceuticals will acquire exclusive US rights to Zurampic from AstraZeneca...
22 April 2016 | By Victoria White, Digital Content Producer
TapImmune plans to initiate a Phase II trial of TPIV 200 in combination with AstraZeneca’s durvalumab in patients with platinum-resistant ovarian cancer...
15 April 2016 | By Victoria White, Digital Content Producer
AstraZeneca has reported new Phase I extended follow-up data on osimertinib in both first- and second-line treatment of patients with non-small cell lung cancer (NSCLC).
8 April 2016 | By Victoria White
AstraZeneca and Lilly have announced that AMARANTH, a Phase II/III study of AZD3293 will continue into Phase III of the Phase II/III seamless trial...
5 April 2016 | By Victoria White
This recommendation allows a vaccine containing a strain of pandemic potential to be developed and authorised in advance of a pandemic being declared...
23 March 2016 | By Victoria White
The SOCRATES trial evaluated Brilinta (ticagrelor) versus aspirin for the prevention of major vascular events in patients with an acute ischaemic stroke...
8 March 2016 | By Victoria White
The approval expands the use of Faslodex and offers additional options for US women with HR+, HER2- metastatic breast cancer…
1 March 2016 | By Victoria White
ProStrakan will make an upfront payment to AstraZeneca of $70 million to acquire the rights to Moventig in the EU, Iceland, Norway, Switzerland and Liechtenstein...
29 February 2016 | By Victoria White
DETERMINE, the Phase IIb clinical trial of tremelimumab monotherapy in second or third-line treatment of unresectable malignant mesothelioma, did not meet its primary endpoint of overall survival...
